Bioatla Inc (BCAB) Stock Price, Quote & News

Latest News on BCAB

Dec 20, 2024, 9:00 AM EST - 4 weeks ago

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

Dec 16, 2024, 8:00 AM EST - 4 weeks ago

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Dec 10, 2024, 8:00 AM EST - 5 weeks ago

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Nov 9, 2024, 8:53 AM EST - 2 months ago

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

Oct 8, 2024, 6:12 AM EDT - 3 months ago

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

Oct 7, 2024, 11:29 AM EDT - 3 months ago

BioAtla: Numerous Catalysts Coming In Q4

Oct 4, 2024, 9:05 AM EDT - 3 months ago

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Oct 1, 2024, 8:00 AM EDT - 3 months ago

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Sep 23, 2024, 7:30 AM EDT - 4 months ago

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Aug 11, 2024, 1:32 AM EDT - 5 months ago

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

Jul 25, 2024, 5:39 PM EDT - 6 months ago

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

May 29, 2024, 8:00 AM EDT - 8 months ago

BioAtla to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 8 months ago

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 14, 2024, 8:35 PM EDT - 8 months ago

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:05 PM EDT - 8 months ago

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

May 8, 2024, 8:00 AM EDT - 9 months ago

BioAtla to Participate in the Citizens JMP Life Sciences Conference

May 7, 2024, 8:00 AM EDT - 9 months ago

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

May 6, 2024, 8:00 AM EDT - 9 months ago

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

May 2, 2024, 10:03 AM EDT - 9 months ago

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

Apr 24, 2024, 4:35 PM EDT - 9 months ago

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 26, 2024, 7:21 PM EDT - 10 months ago

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 4:01 PM EDT - 10 months ago

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Mar 19, 2024, 8:00 AM EDT - 10 months ago

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

Mar 7, 2024, 8:00 AM EST - 11 months ago

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Dec 20, 2023, 8:00 AM EST - 1 year ago

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 13, 2023, 8:00 AM EST - 1 year ago

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Dec 6, 2023, 8:00 AM EST - 1 year ago

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

Dec 5, 2023, 8:00 AM EST - 1 year ago

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

Nov 30, 2023, 8:00 AM EST - 1 year ago

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

Nov 28, 2023, 8:00 AM EST - 1 year ago

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

Nov 12, 2023, 5:38 AM EST - 1 year ago

BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:01 PM EST - 1 year ago

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

Nov 6, 2023, 4:05 PM EST - 1 year ago

BioAtla to Participate in the Jefferies London Healthcare Conference

Oct 12, 2023, 7:30 AM EDT - 1 year ago

BioAtla's Jay M. Short, Ph.D.

Oct 10, 2023, 7:30 AM EDT - 1 year ago

BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023

Sep 6, 2023, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 4:01 PM EDT - 1 year ago

BioAtla to Participate in Upcoming Investor Conferences in August

Aug 1, 2023, 11:18 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q2 2023 Earnings Call Transcript

Aug 1, 2023, 4:01 PM EDT - 1 year ago

BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress

Jul 25, 2023, 8:00 AM EDT - 1 year ago

BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023

Jun 26, 2023, 8:00 AM EDT - 1 year ago

BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index

May 31, 2023, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Jefferies Healthcare Conference

May 11, 2023, 10:51 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q1 2023 Earnings Call Transcript

May 11, 2023, 4:01 PM EDT - 1 year ago

BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

May 8, 2023, 4:05 PM EDT - 1 year ago

BioAtla to Participate in the JMP Securities Life Sciences Conference

May 4, 2023, 8:00 AM EDT - 1 year ago

BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023

Mar 23, 2023, 10:33 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q4 2022 Earnings Call Transcript

Mar 23, 2023, 4:05 PM EDT - 1 year ago

BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

Mar 16, 2023, 8:00 AM EDT - 2 years ago

BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights

Feb 27, 2023, 8:07 AM EST - 2 years ago

Market Cap	23.49M
Revenue (ttm)	0.00
Net Income (ttm)	-123.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	375,200
Avg Vol	1,236,858
Day's Range	N/A - N/A
Shares Out	48.35M
Stochastic %K	18%
Beta	1.17
Analysts	Strong Sell
Price Target	$10.67